Schlagwort: EMBL Ventures
“We still believe we’re an undiscovered gem.”
What drives an experienced biotech leader to join a company like TOPAS, and why does he believe that they’re an undiscovered gem in the...
New funding concepts for translational projects
The biotech scene in Germany is growing continuously – slowly but steadily, despite the ongoing shortcomings of the European risk capital market. While funding...
Topas erzielt Serie A-Finanzierung von 14 Mio. EUR
Die Topas Therapeutics GmbH, spezialisiert auf die Erforschung von Autoimmunkrankheiten, hat eine Serie A-Finanzierungsrunde in Höhe von 14 Mio. EUR abschließen können.
ViraTherapeutics: First closing of Series A financing
ViraTherapeutics (ViraT), a privately held biopharmaceutical company developing cancer immunotherapies based on cancer-destroying viruses, announces the first closing of a Series A financing round, raising 3,6 Mio. EUR.